Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JB-141
- Development stage
- Preclinical
- Lead developer
- Junten Bio
01
Overview
JB-141 is an investigational drug candidate currently in the preclinical stage of development by Junten Bio. It is being developed for applications in organ transplantation, likely aimed at inducing immune tolerance to prevent graft rejection. Junten Bio specializes in developing therapies that modulate the immune system, including inducible inhibitory T-cell therapies and monoclonal antibodies, to reduce the need for long-term immunosuppression in transplant patients. Specific details regarding the modality and molecular target of JB-141 have not been publicly disclosed, but it is part of a broader pipeline focused on achieving transplant tolerance and treating hyperimmune-related diseases.
Beyond the preview
Go deeper on JB-141.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JB-141.